查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1809668

女性不孕症诊断与治疗市场（治疗方法、诊断技术、不孕症类型与通路）－2025-2030 年全球预测

Female Infertility Diagnosis & Treatment Market by Treatment Method, Diagnosis Technique, Type of Infertility, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年女性不孕症诊断和治疗市场价值为 49 亿美元，预计 2025 年将成长至 52.9 亿美元，复合年增长率为 8.14%，预计到 2030 年将达到 78.5 亿美元。

主要市场统计数据
基准年2024年 49亿美元
预计2025年 52.9亿美元
预测年份 2030 78.5亿美元
复合年增长率（%） 8.14%

女性不孕症诊断和治疗领域的新兴动态凸显了整个医疗生态系统相关人员面临的重大挑战和机会

在患者期望不断变化和技术突破的推动下，女性不孕症的诊断和治疗已成为生殖医学领域的关键关注领域。过去十年，随着人们对不孕症问题的认识不断提高，加之人口结构向晚育转变，对精密诊断工具和个人化治疗方法的需求空前高涨。因此，医疗保健提供者和产品开发者被迫改进临床通讯协定，并引入创新解决方案，以提高成功率，同时最大限度地减轻患者负担。

关键技术和临床变化将重新定义女性不孕症的诊断和治疗前景，改善患者的治疗结果和治疗途径

诊断和治疗技术的快速创新正在从根本上改变女性不孕症的格局，掀起一股变革浪潮，有望提高疗效并改善患者体验。新的生物标记组合和次世代定序提高了基因检测的准确性，使医生能够更自信地识别染色体异常和遗传风险因素。这些基因洞察如今正为制定标靶治疗方案提供讯息，从而优化刺激方案和胚胎选择标准。

评估美国关税调整对女性不孕症诊断和治疗供应链和成本结构的广泛影响

美国对进口医疗设备、检测试剂和药物化合物征收的新关税于2025年初生效，给支持女性不孕症治疗的供应链带来了新的挑战。设备製造商面临超音波探头和孵化器的投入成本增加，而诊断剂供应商则面临基因检测套组关税增加。因此，诊所和实验室必须重新评估筹资策略，以维持病患的价格稳定。

深入研究治疗方法、诊断技术、不孕症类型和销售管道，揭示市场区隔的动态

深入了解市场细分可以揭示女性不孕症服务成长和差异化的关键途径。治疗方法可分为辅助生殖技术、冷冻保存、不孕症药物和外科手术介入。辅助生殖技术包括输卵管内配子移植、体外受精、卵细胞质内单一精虫显微注射术及子宫内授精等技术。在冷冻保存领域，胚胎、卵子和精子储存的进步正在推动患者对不孕症治疗方案的需求。生育药物包括克罗米芬柠檬酸盐、促性腺激素分泌和来曲唑，每种药物都有不同的风险效益特征。外科手术介入包括子宫镜、腹腔镜检查、肌瘤切除术和输卵管手术，每种手术都针对特定的解剖或病理状况量身定制。

评估美洲、中东/非洲和亚太地区女性不孕症诊断和治疗趋势的区域差异

区域动态在影响女性不孕症诊断和治疗方法的可及性、报销和采用率方面发挥关键作用。在美洲，不断扩大的私人医疗网络和辅助生殖技术保险覆盖范围的扩大，正在推动诊所的扩张和患者数量的增加。北美的法律规范不断发展，一些州允许生殖旅游和跨境治疗拥有更大的自主权，而拉丁美洲市场则正在利用具有成本效益的服务模式来吸引国际患者。

介绍产业领导者及其推动女性不孕症诊断和治疗解决方案创新的策略性倡议

女性不孕症领域的主要企业正在利用策略伙伴关係、研发投入和地理扩张等多种手段来巩固其市场地位。诊断创新者正在与学术机构合作，检验生物标记的发现；而设备製造商则正在推出合资企业，共同开发整合式试管婴儿实验室主机。製药公司正在加强其下一代生育治疗的后期临床研发管线，旨在降低週期取消率，并最大程度地减少卵巢刺激相关的副作用。

产业领导者增强竞争力、推动女性不孕症护理永续发展的策略挑战和实际步骤

寻求保持竞争力的行业领导者必须采取多管齐下的策略，在技术创新与以患者为中心的护理模式之间取得平衡。首先，将内部研发重点与新兴临床需求（例如非侵入性胚胎诊断和单细胞基因检测）结合，可以释放新的价值提案。同时，投资模组化实践架构和数位健康平台，可以实现跨地域的可扩展服务交付。

详细描述女性生育治疗创新研究框架的资料来源和分析方法

本研究采用综合研究框架，将一手资料、二手资料和专家检验结合，以提供可靠且可操作的见解。一手资料研究包括与生殖专家、实验室主任和供应链经理进行结构化讨论，以获得关于技术应用和营运挑战的第一手观点。二手资料来源包括同侪审查日誌、监管备案文件和临床试验註册中心，以整理新兴趋势与既定证据。

影响女性不孕症诊断和治疗性介入未来的关键发现和策略观点的摘要

本执行摘要概述了影响女性不孕症诊断和治疗的关键驱动因素、新兴技术和策略考虑。从先进的基因检测方法和人工智慧成像平台，到新资费政策对营运的影响，该领域正在迅速演变。透过对治疗方式、诊断技术、不孕症类型和分销管道的细分，我们可以多角度地了解市场的复杂性和患者需求。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 将人工智慧演算法融入个人化生育治疗计划
  • 越来越多地采用远端医疗平台进行虚拟生育咨询和远端监控
  • 扩展家庭荷尔蒙监测解决方案，以便早期发现排卵障碍
  • 非侵入性子宫内膜容受性检测的进展提高了胚胎移植的成功率
  • 越来越多地使用微流体精子分选技术来提高体外受精週期中的受精成功率
  • 将肠道微生物分析整合到生育能力评估中，以製定个人化治疗决策
  • 支持扩大非处方不孕症诊断试剂套件和服务的监管变化
  • 新兴的个人化卵巢组织冷冻保存通讯协定可改善生育力保存结果
  • 以患者为中心的数位支援工具在减轻不孕症治疗期间的精神压力方面的重要性日益凸显
  • 以患者为中心的数位支援平台在生育治疗期间提供情感护理工具和社区参与。

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：女性不孕症诊断与治疗市场（依治疗方法）

  • 辅助生殖技术
    • 配子输卵管植入
    • 体外受精
    • 卵细胞质内单一精虫显微注射术
    • 子宫内人工授精
  • 冷冻保存
    • 胚胎冷冻保存
    • 卵子冷冻保存
    • 精子冷冻保存
  • 生育药物
    • 克罗米芬柠檬酸盐
    • 促性腺激素分泌
    • 来曲唑
  • 外科手术干预
    • 子宫镜手术
    • 腹腔镜手术
    • 子宫肌瘤切除术
    • 输卵管手术

9. 女性不孕症诊断与治疗市场（依诊断技术）

  • 血液学诊断
    • 抗穆氏管荷尔蒙检测
    • 滤泡刺激素检测
    • 黄体激素检测
    • 催乳素测试
  • 基因检测
  • 造影
  • 腹腔镜检查
  • 超音波影像

第 10 章：女性不孕症诊断与治疗市场（依不孕症类型）

  • 原发性不孕症
  • 续发性不孕症

第 11 章：女性不孕症诊断与治疗市场（依通路）

  • 诊所服务
    • 妇科综合诊所
    • 专科不孕症诊所
  • 居家照护测试
  • 医院服务
  • 独立研究机构

12.美国女性不孕症诊断与治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 欧洲、中东和非洲女性不孕症诊断与治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

14. 亚太女性不孕症诊断与治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Ferring BV
    • Thermo Fisher Scientific Inc.
    • Abbott Diagnostics
    • Bayer AG
    • Cook Group Incorporated
    • CooperSurgical Inc.
    • F. Hoffmann-La Roche Ltd.
    • FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation
    • Genea Pty Limited
    • GlaxoSmithKline PLC
    • Halotech DNA SL
    • Merck & Co., Inc.
    • Qiagen NV
    • Theramex by Kanga Health Ltd.

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

Product Code: MRR-FE70EC183B6E

The Female Infertility Diagnosis & Treatment Market was valued at USD 4.90 billion in 2024 and is projected to grow to USD 5.29 billion in 2025, with a CAGR of 8.14%, reaching USD 7.85 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.90 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2030] USD 7.85 billion
CAGR (%) 8.14%

Emerging Dynamics in Female Infertility Diagnosis and Treatment Highlighting Critical Challenges and Opportunities for Stakeholders Across Healthcare Ecosystems

Female infertility diagnosis and treatment has emerged as a critical focal area within reproductive health, driven by evolving patient expectations and technological breakthroughs. Over the past decade, increasing awareness of infertility issues, coupled with demographic shifts toward delayed childbearing, has created unprecedented demand for sophisticated diagnostic tools and tailored treatment modalities. Consequently, healthcare providers and product developers are under pressure to refine clinical protocols and introduce innovative solutions that enhance success rates while minimizing patient burden.

Building on these dynamics, diagnostic blood panels and advanced imaging techniques are now complemented by genetic testing capabilities that offer deeper insights into underlying causes of infertility. In parallel, treatment paradigms have transcended conventional ovulation induction to integrate personalized regimens encompassing in vitro fertilization enhancements and cryopreservation refinements. These advances underscore the importance of coordinated care teams who can navigate complex treatment pathways and ensure comprehensive support from initial evaluation through to embryo transfer.

Moreover, regulatory agencies have begun to harmonize guidelines for assisted reproductive technologies, paving the way for broader adoption and insurance reimbursement frameworks. As a result, market participants must align their development pipelines with evolving compliance standards to mitigate risk while capturing emerging opportunities. In this landscape, stakeholders-from clinicians to laboratory specialists-must collaborate seamlessly to translate cutting-edge research into actionable care protocols that deliver tangible outcomes for patients.

Key Technological and Clinical Shifts Redefining the Landscape of Female Infertility Diagnosis and Treatment for Enhanced Patient Outcomes and Care Pathways

Rapid innovations in diagnostic and therapeutic technologies have fundamentally altered the female infertility landscape, creating a wave of transformative shifts that promise improved efficacy and patient experience. Novel biomarker panels and next-generation sequencing have elevated the precision of genetic testing, enabling practitioners to identify chromosomal abnormalities and hereditary risk factors with greater confidence. This genetic insight is now informing targeted treatment plans that optimize stimulation protocols and embryo selection criteria.

Simultaneously, the integration of artificial intelligence into ultrasound imaging and decision-support systems has streamlined clinical workflows, reducing time to diagnosis and enhancing predictive accuracy for treatment outcomes. Meanwhile, refinements in cryopreservation techniques-such as vitrification-have significantly improved post-thaw survival rates of oocytes and embryos, offering greater flexibility in cycle scheduling and enabling fertility preservation initiatives for oncological and elective cases alike.

Telehealth platforms have also emerged as critical enablers, allowing remote monitoring of hormone levels and follicular development. This shift toward hybrid care models not only increases patient convenience but also optimizes resource utilization in fertility clinics. Moreover, the growing emphasis on personalized medicine is driving pharmaceutical research toward novel fertility medications that act on specific receptor pathways, reducing adverse effects while enhancing ovarian response. These interrelated developments collectively mark a pivotal evolution in the way infertility is diagnosed, managed, and treated.

Assessing the Widespread Effects of United States Tariff Adjustments on the Supply Chain and Cost Structures in Female Infertility Diagnosis and Treatment

In early 2025, the implementation of new United States tariffs on imported medical devices, laboratory reagents, and pharmaceutical compounds has introduced fresh challenges to the supply chain underpinning female infertility services. Equipment manufacturers have experienced higher input costs for ultrasound probes and incubators, while diagnostic reagent suppliers face elevated duties on genetic testing kits. As a result, clinics and laboratories must reassess procurement strategies to maintain price stability for patients.

Beyond cost considerations, the tariffs have spurred manufacturers to explore alternative sourcing options, including regional production hubs in North America and trade agreements with non-tariffed partners. Although these adaptations require upfront investment, they are expected to mitigate long-term exposure to volatile trade policies. In the short term, however, some smaller independent laboratories may experience budgetary strain, leading to potential consolidation within the market as larger service providers absorb or partner with struggling units.

Additionally, pharmaceutical companies that rely on imported active pharmaceutical ingredients for fertility medications have encountered supply delays, which in turn affect treatment scheduling and patient satisfaction. In response, several stakeholders are negotiating direct supply contracts and investing in domestic API production capacities. This cumulative impact of tariff adjustments highlights the need for agile supply chain management and underscores the importance of diversifying sourcing strategies to preserve continuity of care in female infertility diagnosis and treatment.

Deep Dive into Treatment Methods Diagnosis Techniques Infertility Types and Distribution Channels Revealing Nuanced Market Segmentation Dynamics

A nuanced understanding of market segmentation reveals critical avenues for growth and differentiation in female infertility services. Treatment methods can be categorized across assisted reproductive technology, cryopreservation, fertility medications, and surgical intervention, with assisted reproductive technology encompassing techniques such as gamete intrafallopian transfer, in vitro fertilization, intracytoplasmic sperm injection, and intrauterine insemination. Within cryopreservation, advances in embryo, oocyte, and sperm preservation are driving patient demand for fertility preservation options. Fertility medications range from clomiphene citrate to gonadotropins and letrozole, each offering distinct risk-benefit profiles. Surgical interventions include hysteroscopic and laparoscopic surgeries, myomectomy, and tubal surgery, each tailored to specific anatomical or pathological conditions.

Diagnosis techniques further refine service offerings through blood diagnostics, genetic testing, hysterosalpingography, laparoscopy, and ultrasound imaging. Blood diagnostics panels include anti-Mullerian hormone, follicle stimulating hormone, luteinizing hormone, and prolactin assays, enabling clinicians to personalize treatment protocols based on ovarian reserve and endocrine function. Type of infertility segmentation differentiates between primary and secondary infertility, highlighting distinct patient journeys and clinical considerations. Distribution channels cover clinic services, home care testing, hospital services, and independent laboratories, with clinic services divided into general gynecology clinics and specialized fertility centers. Together, these segmentation insights inform strategic decisions on service design, resource allocation, and targeted patient engagement across the continuum of care.

Evaluating Regional Variations Across Americas Europe Middle East Africa and Asia Pacific in Female Infertility Diagnosis and Treatment Trends

Regional dynamics play a pivotal role in shaping access, reimbursement, and adoption rates for female infertility diagnosis and treatment modalities. In the Americas, expansive private healthcare networks and growing insurance coverage for assisted reproductive technology have fueled clinic expansions and increased patient throughput. Regulatory frameworks in North America continue to evolve, with some states granting greater autonomy in reproductive tourism and cross-border care, while Latin American markets leverage cost-effective service models to attract international patients.

Within Europe, Middle East & Africa, diverse healthcare infrastructures and reimbursement policies create a fragmented landscape. Western European nations benefit from comprehensive insurance schemes and well-established fertility networks, whereas in emerging markets in the Middle East and North Africa, government-backed initiatives are accelerating the construction of specialty clinics. Compliance requirements differ significantly across jurisdictions, requiring product developers and service providers to tailor market entry strategies accordingly.

Asia-Pacific has emerged as a high-growth region, driven by demographic trends toward delayed parenthood in urban centers. Nations such as Japan and South Korea lead in technological adoption, while India and Southeast Asian countries compete on affordability and service volume, attracting patients from neighboring regions. Government incentives for domestic manufacturing and telehealth expansions further amplify the region's potential. As a result, stakeholders must develop multi-regional playbooks that account for the unique regulatory, cultural, and economic factors influencing demand for fertility services across these diverse markets.

Profiling Leading Industry Players and Their Strategic Initiatives Driving Innovation in Female Infertility Diagnosis and Treatment Solutions

Leading players in the female infertility space are leveraging a mix of strategic partnerships, R&D investments, and geographic expansion to strengthen their market position. Diagnostic innovators are pursuing collaborations with academic institutions to validate biomarker discovery, while equipment manufacturers are entering joint ventures to co-develop integrated IVF lab consoles. Pharmaceutical companies are bolstering late-stage clinical pipelines for next-generation fertility drugs, aiming to reduce cycle cancellation rates and minimize side effects associated with ovarian stimulation.

Notably, several laboratory service providers have adopted digital platforms that harmonize patient data from disparate testing modalities, offering seamless clinician access and automated reporting. Some firms are also acquiring smaller boutique labs to broaden their test menus and consolidate technical expertise under a unified quality management system. Companies in cryopreservation have introduced proprietary vitrification solutions, emphasizing post-thaw viability and ease of use for embryologists.

Concurrent with these innovations, market leaders are expanding into underserved regions through greenfield clinic openings and franchise models. They are also establishing patient support programs that encompass financial counseling, psychological services, and telemedicine follow-ups, enhancing patient adherence and satisfaction. Collectively, these strategic moves illustrate how companies are shaping the competitive landscape and accelerating the translation of novel technologies into routine clinical practice.

Strategic Imperatives and Practical Steps for Industry Leaders to Enhance Competitiveness and Foster Sustainable Growth in Female Infertility Care

Industry leaders seeking to maintain a competitive edge must adopt a multi-pronged strategy that balances technological innovation with patient-centric care models. First, aligning internal R&D priorities with emerging clinical needs-such as non-invasive embryo diagnostics and single-cell genetic assays-can unlock new value propositions. Simultaneously, investing in modular clinic architectures and digital health platforms will enable scalable service delivery across diverse geographies.

Next, fostering cross-sector partnerships with supply chain specialists and telehealth providers can optimize cost structures and extend remote monitoring capabilities. By integrating real-time data analytics into patient management systems, organizations can predict treatment responses and proactively adjust protocols to improve outcomes. Additionally, standardizing quality metrics and publishing outcome data will enhance transparency and build trust among prospective patients and payers.

Finally, embracing agile regulatory pathways and engaging with health authorities early in the development cycle can expedite product approvals and reimbursement alignment. Establishing centers of excellence for training clinicians and laboratory personnel will ensure consistent protocol adherence, while patient education initiatives can demystify treatment options and improve engagement. These actionable steps, taken in concert, will position industry leaders to deliver superior clinical efficacy, operational efficiency, and patient satisfaction.

In-Depth Explanation of the Research Framework Data Sources and Analytical Approaches Underpinning the Study on Female Infertility Care Innovations

This study employed a comprehensive research framework combining primary interviews, secondary data triangulation, and expert validation to ensure robust and actionable insights. Primary research involved structured discussions with fertility specialists, laboratory directors, and supply chain managers to capture firsthand perspectives on technology adoption and operational challenges. Secondary sources included peer-reviewed journals, regulatory filings, and clinical trial registries to contextualize emerging trends against established evidence.

Quantitative analysis leveraged anonymized case series from leading clinics, while qualitative synthesis distilled strategic narratives from stakeholder interviews. Data sources were meticulously cross-referenced to identify convergent themes and outliers, thereby enhancing the reliability of key findings. The team applied scenario planning techniques to assess the potential impact of policy changes, such as tariff adjustments and regulatory updates, on market dynamics.

Expert validation panels provided iterative feedback on draft frameworks, ensuring that segmentation schemas and regional insights accurately reflected real-world conditions. Ethical guidelines and data privacy standards were rigorously maintained throughout the research process. This mixed-methodology approach underpins the credibility of the study, offering decision-makers a transparent pathway from raw data to strategic recommendations.

Summarizing Pivotal Findings and the Strategic Outlook Poised to Shape the Future of Female Infertility Diagnosis and Therapeutic Interventions

This executive summary has illuminated key drivers, emerging technologies, and strategic considerations shaping female infertility diagnosis and treatment. From advanced genetic testing methodologies and AI-enabled imaging platforms to the operational ramifications of new tariff policies, the landscape is in a state of rapid evolution. Segmentations across treatment methods, diagnostic techniques, infertility types, and distribution channels provide a multidimensional view of market complexities and patient needs.

Regional analyses underscore the importance of tailored strategies, as dynamic regulatory environments and economic factors influence adoption rates in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Case studies of leading companies reveal how strategic collaborations, targeted R&D, and patient support initiatives are redefining competitive advantages. Actionable recommendations emphasize the integration of digital health, quality standardization, and agile regulatory engagement to drive sustainable growth.

Looking ahead, the confluence of personalized medicine and data-driven decision support will continue to unlock higher success rates and optimize resource utilization. Stakeholders who proactively adapt to these trends-while maintaining a steadfast commitment to patient-centered care-will be best positioned to lead the next wave of innovation in female infertility treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of artificial intelligence algorithms in personalized infertility treatment planning
  • 5.2. Growing adoption of telehealth platforms for virtual fertility consultations and remote monitoring
  • 5.3. Expansion of at home hormone monitoring solutions for early detection of ovulatory disorders
  • 5.4. Advances in non invasive endometrial receptivity assays improving embryo transfer success rates
  • 5.5. Increased use of microfluidic sperm sorting technologies to improve fertilization success in ivf cycles
  • 5.6. Integration of gut microbiome profiling in fertility assessments to personalize treatment decisions
  • 5.7. Regulatory shifts favoring expansion of over the counter fertility diagnostic kits and services
  • 5.8. Emergence of personalized ovarian tissue cryopreservation protocols enhancing fertility preservation outcomes
  • 5.9. Growing emphasis on patient centered digital support tools to reduce emotional stress during infertility treatment
  • 5.10. Patient-centered digital support platforms provide emotional care tools and community engagement during infertility treatments

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Female Infertility Diagnosis & Treatment Market, by Treatment Method

  • 8.1. Introduction
  • 8.2. Assisted Reproductive Technology
    • 8.2.1. Gamete Intrafallopian Transfer
    • 8.2.2. In Vitro Fertilization
    • 8.2.3. Intracytoplasmic Sperm Injection
    • 8.2.4. Intrauterine Insemination
  • 8.3. Cryopreservation
    • 8.3.1. Embryo Cryopreservation
    • 8.3.2. Oocyte Cryopreservation
    • 8.3.3. Sperm Cryopreservation
  • 8.4. Fertility Medications
    • 8.4.1. Clomiphene Citrate
    • 8.4.2. Gonadotropins
    • 8.4.3. Letrozole
  • 8.5. Surgical Intervention
    • 8.5.1. Hysteroscopic Surgery
    • 8.5.2. Laparoscopic Surgery
    • 8.5.3. Myomectomy
    • 8.5.4. Tubal Surgery

9. Female Infertility Diagnosis & Treatment Market, by Diagnosis Technique

  • 9.1. Introduction
  • 9.2. Blood Diagnostics
    • 9.2.1. Anti Mullerian Hormone Test
    • 9.2.2. Follicle Stimulating Hormone Test
    • 9.2.3. Luteinizing Hormone Test
    • 9.2.4. Prolactin Test
  • 9.3. Genetic Testing
  • 9.4. Hysterosalpingography
  • 9.5. Laparoscopy
  • 9.6. Ultrasound Imaging

10. Female Infertility Diagnosis & Treatment Market, by Type of Infertility

  • 10.1. Introduction
  • 10.2. Primary Infertility
  • 10.3. Secondary Infertility

11. Female Infertility Diagnosis & Treatment Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Clinic Services
    • 11.2.1. General Gynecology Clinics
    • 11.2.2. Specialized Fertility Clinics
  • 11.3. Home Care Testing
  • 11.4. Hospital Services
  • 11.5. Independent Laboratories

12. Americas Female Infertility Diagnosis & Treatment Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Female Infertility Diagnosis & Treatment Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Female Infertility Diagnosis & Treatment Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ferring B.V.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Abbott Diagnostics
    • 15.3.4. Bayer AG
    • 15.3.5. Cook Group Incorporated
    • 15.3.6. CooperSurgical Inc.
    • 15.3.7. F. Hoffmann-La Roche Ltd.
    • 15.3.8. FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation
    • 15.3.9. Genea Pty Limited
    • 15.3.10. GlaxoSmithKline PLC
    • 15.3.11. Halotech DNA S.L.
    • 15.3.12. Merck & Co., Inc.
    • 15.3.13. Qiagen N.V.
    • 15.3.14. Theramex by Kanga Health Ltd.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHAI
  • FIGURE 24. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 25. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 26. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY OOCYTE CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY OOCYTE CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPERM CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPERM CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSCOPIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TUBAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TUBAL SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ANTI MULLERIAN HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ANTI MULLERIAN HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FOLLICLE STIMULATING HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FOLLICLE STIMULATING HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LUTEINIZING HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LUTEINIZING HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROLACTIN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROLACTIN TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRIMARY INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRIMARY INFERTILITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SECONDARY INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SECONDARY INFERTILITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENERAL GYNECOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GENERAL GYNECOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALIZED FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALIZED FERTILITY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME CARE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINIC SERVICES, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT METHOD, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY MEDICATIONS, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TECHNIQUE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BLOOD DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TYPE OF INFERTILITY, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DI